Trailing-twelve-month (TTM) revenue is $587.89 Million with a year-over-year growth of (11.47%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $151,669,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-29 |
| Q4 FY2025Period ended 2025-12-31 | $148,450,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-26 |
| Q1 FY2026Period ended 2026-03-31 | $124,196,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-28 |
| Q2 FY2026Period ended 2026-06-30 | $163,580,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-27 |
| TTM revenue | $587,895,000 |
Current P/S: $1,134,418,902 market capitalization ÷ $587,895,000 TTM revenue = 1.93x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T16:10:18.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $163.58M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T16:13:28.766Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Client Payers | $638M | N/A | N/A | N/A | N/A | N/A |
| Government Payers | $90M | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| CHILE | $44M | $64M | $62M | $68M | $65M | $62M |
| IRELAND | $44M | $33M | $117M | $141M |
$587.89M
$587.89 Million
(11.47%)
vs. $664.06M a year ago (TTM)
(21.00%)
5 Year compound annual growth rate
1 Year
(11.47%)
3 Year
(12.18%)
5 Year
(21.00%)
10 Year
(5.79%)
15 Year
+20.27%
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $606.88M | ($106.26M) | (14.90%) |
| 2024 | $713.14M | ($150.35M) | (17.41%) |
| 2023 | $863.50M | ($140.70M) | (14.01%) |
| 2022 | $1.00B | ($770.52M) | (43.42%) |
| 2021 | $1.77B | +$339.31M | +23.64% |
| 2020 |
TTM Growth
(11.47%)
3-Year CAGR
(12.18%)
5-Year CAGR
(21.00%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T16:13:28.766Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| N/A |
| N/A |
| N/A |
| Health Insurers | $484M | N/A | N/A | N/A | N/A | N/A |
|---|
| Patients | $51M | N/A | N/A | N/A | N/A | N/A |
|---|
| Product | $120M | $142M | $143M | $168M | $155M | $157M |
|---|
| Rayaldee | $88M | N/A | N/A | N/A | N/A | N/A |
|---|
| Service | $1.3B | $1.6B | $756M | $515M | $481M | $370M |
|---|
| Transfer of Intellectual Property and Other | N/A | $26M | $106M | $181M | $77M | $80M |
|---|
| Transfer Of Intellectual Property And Other | $29M | N/A | N/A | N/A | N/A | N/A |
|---|
| $51M |
| ISRAEL | $4M | $4M | $4M | $10M | $2M | $522,000 |
|---|
| MEXICO | $8M | $11M | $15M | $20M | $24M | $26M |
|---|
| Other Countries | $526,000 | $507,000 | $863,000 | $2M | $3M | $4M |
|---|
| SPAIN | $17M | $23M | $22M | $24M | $25M | $27M |
|---|
| UNITED STATES | $1.3B | $1.6B | $783M | $598M | $546M | $436M |
|---|
| $1.44B |
| +$533.48M |
| +59.15% |
| 2019 | $901.93M | ($88.36M) | (8.92%) |
| 2018 | $990.30M | +$24.29M | +2.51% |
| 2017 | $966.01M | ($255.69M) | (20.93%) |
| 2016 | $1.22B | +$730.00M | +148.46% |
